https://www.statnews.com/2019/01/07/eli-lilly-to-acquire-loxo/
A huge stock in cancer genetics. Loxo has drugs that are best-in-class in treating tumors where the patient has a certain genetic mutation.
Competitors include Blueprint Medicines ($BPMC) and Deciphera Pharmaceuticals ($DCPH)
Submitted January 07, 2019 at 07:19AM by myracksarecabbage http://bit.ly/2RBMm94
